271 related articles for article (PubMed ID: 18182473)
1. Multi-matrix system mesalamine: to use or not to use.
Kale-Pradhan PB; Pradhan RS; Wilhelm SM
Ann Pharmacother; 2008 Feb; 42(2):265-9. PubMed ID: 18182473
[TBL] [Abstract][Full Text] [Related]
2. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis.
Lichtenstein GR; Kamm MA; Boddu P; Gubergrits N; Lyne A; Butler T; Lees K; Joseph RE; Sandborn WJ
Clin Gastroenterol Hepatol; 2007 Jan; 5(1):95-102. PubMed ID: 17234558
[TBL] [Abstract][Full Text] [Related]
3. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis.
Kamm MA; Sandborn WJ; Gassull M; Schreiber S; Jackowski L; Butler T; Lyne A; Stephenson D; Palmen M; Joseph RE
Gastroenterology; 2007 Jan; 132(1):66-75; quiz 432-3. PubMed ID: 17241860
[TBL] [Abstract][Full Text] [Related]
4. Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study.
D'Haens G; Hommes D; Engels L; Baert F; van der Waaij L; Connor P; Ramage J; Dewit O; Palmen M; Stephenson D; Joseph R
Aliment Pharmacol Ther; 2006 Oct; 24(7):1087-97. PubMed ID: 16984503
[TBL] [Abstract][Full Text] [Related]
5. Once-daily MMX(®) mesalamine for endoscopic maintenance of remission of ulcerative colitis.
D'Haens G; Sandborn WJ; Barrett K; Hodgson I; Streck P
Am J Gastroenterol; 2012 Jul; 107(7):1064-77. PubMed ID: 22565161
[TBL] [Abstract][Full Text] [Related]
6. MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations.
Lichtenstein GR; Kamm MA; Sandborn WJ; Lyne A; Joseph RE
Aliment Pharmacol Ther; 2008 Jun; 27(11):1094-102. PubMed ID: 18363894
[TBL] [Abstract][Full Text] [Related]
7. Mesalamine with MMX technology for the treatment of ulcerative colitis.
Schreiber S; Kamm MA; Lichtenstein GR
Expert Rev Gastroenterol Hepatol; 2008 Jun; 2(3):299-314. PubMed ID: 19072380
[TBL] [Abstract][Full Text] [Related]
8. Extended-release mesalamine granules for ulcerative colitis.
Love BL; Miller AD
Ann Pharmacother; 2012 Nov; 46(11):1529-36. PubMed ID: 23115226
[TBL] [Abstract][Full Text] [Related]
9. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis.
Dignass AU; Bokemeyer B; Adamek H; Mross M; Vinter-Jensen L; Börner N; Silvennoinen J; Tan G; Pool MO; Stijnen T; Dietel P; Klugmann T; Vermeire S; Bhatt A; Veerman H
Clin Gastroenterol Hepatol; 2009 Jul; 7(7):762-9. PubMed ID: 19375519
[TBL] [Abstract][Full Text] [Related]
10. Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol.
Prantera C; Kohn A; Campieri M; Caprilli R; Cottone M; Pallone F; Savarino V; Sturniolo GC; Vecchi M; Ardia A; Bellinvia S
Aliment Pharmacol Ther; 2009 Nov; 30(9):908-18. PubMed ID: 19678813
[TBL] [Abstract][Full Text] [Related]
11. MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials.
Sandborn WJ; Kamm MA; Lichtenstein GR; Lyne A; Butler T; Joseph RE
Aliment Pharmacol Ther; 2007 Jul; 26(2):205-15. PubMed ID: 17593066
[TBL] [Abstract][Full Text] [Related]
12. Reformulation of an aminosalicylate: an example of the importance of pill burden on medical compliance rates.
Osterman MT; Lichtenstein GR
Methods Find Exp Clin Pharmacol; 2009; 31(1):41-6. PubMed ID: 19357797
[TBL] [Abstract][Full Text] [Related]
13. MMX mesalamine: a novel high-dose, once-daily 5-aminosalicylate formulation for the treatment of ulcerative colitis.
Hu MY; Peppercorn MA
Expert Opin Pharmacother; 2008 Apr; 9(6):1049-58. PubMed ID: 18377346
[TBL] [Abstract][Full Text] [Related]
14. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group.
Hanauer S; Schwartz J; Robinson M; Roufail W; Arora S; Cello J; Safdi M
Am J Gastroenterol; 1993 Aug; 88(8):1188-97. PubMed ID: 8338086
[TBL] [Abstract][Full Text] [Related]
15. Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis.
Sandborn WJ; Korzenik J; Lashner B; Leighton JA; Mahadevan U; Marion JF; Safdi M; Sninsky CA; Patel RM; Friedenberg KA; Dunnmon P; Ramsey D; Kane S
Gastroenterology; 2010 Apr; 138(4):1286-96, 1296.e1-3. PubMed ID: 20064514
[TBL] [Abstract][Full Text] [Related]
16. Multi-Matrix System (MMX®) mesalamine for the treatment of mild-to-moderate ulcerative colitis.
Horst SN; Kane S
Expert Opin Pharmacother; 2012 Oct; 13(15):2225-32. PubMed ID: 22970981
[TBL] [Abstract][Full Text] [Related]
17. MMX mesalamine.
Baker DE
Rev Gastroenterol Disord; 2006; 6(3):146-52. PubMed ID: 16957657
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of a new 3.3 g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study.
Scherl EJ; Pruitt R; Gordon GL; Lamet M; Shaw A; Huang S; Mareya S; Forbes WP
Am J Gastroenterol; 2009 Jun; 104(6):1452-9. PubMed ID: 19491859
[TBL] [Abstract][Full Text] [Related]
19. Mesalazine foam (Salofalk foam) in the treatment of active distal ulcerative colitis. A comparative trial vs Salofalk enema. The SAF-3 study group.
Ardizzone S; Doldo P; Ranzi T; Sturniolo GC; Giglio LA; Annese V; D'Arienzo A; Gaia E; Gullini S; Riegler G; Valentini M; Massa P; Del Piano M; Rossini F; Guidetti CS; Pera A; Greinwald R; Bianchi Porro G
Ital J Gastroenterol Hepatol; 1999 Nov; 31(8):677-84. PubMed ID: 10730559
[TBL] [Abstract][Full Text] [Related]
20. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis.
Cohen RD; Woseth DM; Thisted RA; Hanauer SB
Am J Gastroenterol; 2000 May; 95(5):1263-76. PubMed ID: 10811338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
